Display options
Share it on

Evid Based Complement Alternat Med. 2013;2013:989670. doi: 10.1155/2013/989670. Epub 2013 Oct 28.

Traditional chinese medicine tang-luo-ning ameliorates sciatic nerve injuries in streptozotocin-induced diabetic rats.

Evidence-based complementary and alternative medicine : eCAM

Da-Wei Zou, Yan-Bin Gao, Zhi-Yao Zhu, Hui Zhou, Tao-Jing Zhang, Bu-Man Li, Jin-Yang Wang, Min-Zhou Li, Ming-Fei Ma, Na Zhang

Affiliations

  1. School of Traditional Chinese Medicine, Capital Medical University, Number 10 Youanmenwai Xitoutiao, Fengtai District, Beijing 100069, China.

PMID: 24288572 PMCID: PMC3830865 DOI: 10.1155/2013/989670

Abstract

Diabetic peripheral neuropathy (DPN) is a common microvascular complication of diabetes associated with high disability rate and low quality of life. Tang-Luo-Ning (TLN) is an effective traditional Chinese medicine for the treatment of DPN. To illustrate the underlying neural protection mechanisms of TLN, the effect of TLN on electrophysiology and sciatic nerve morphology was investigated in a model of streptozotocin-induced DPN, as well as the underlying mechanism. Sciatic motor nerve conduction velocity and digital sensory nerve conduction velocity were reduced in DPN and were significantly improved by TLN or α -lipoic acid at 10 and 20 weeks after streptozotocin injection. It was demonstrated that TLN intervention for 20 weeks significantly alleviated pathological injury as well as increased the phosphorylation of ErbB2, Erk, Bad (Ser112), and the mRNA expression of neuregulin 1 (Nrg1), GRB2-associated binding protein 1 (Gab1), and mammalian target of rapamycin (Mtor) in injured sciatic nerve. These novel therapeutic properties of TLN to promote Schwann cell survival may offer a promising alternative medicine for the patients to delay the progression of DPN. The underlying mechanism may be that TLN exerts neural protection effect after sciatic nerve injury through Nrg1/ErbB2→Erk/Bad Schwann cell survival signaling pathway.

References

  1. Circ Res. 1999 Mar 19;84(5):489-97 - PubMed
  2. Can J Physiol Pharmacol. 2006 Jun;84(6):579-87 - PubMed
  3. Neurosci Lett. 2012 Mar 5;511(1):52-7 - PubMed
  4. Exp Diabesity Res. 2003 Oct-Dec;4(4):303-12 - PubMed
  5. Biochem Pharmacol. 2012 Apr 1;83(7):932-40 - PubMed
  6. FASEB J. 2001 Nov;15(13):2508-14 - PubMed
  7. Biochem Pharmacol. 2012 Oct 1;84(7):961-73 - PubMed
  8. J Neurosci. 2006 Mar 22;26(12):3079-86 - PubMed
  9. Neuron. 2005 Sep 1;47(5):681-94 - PubMed
  10. Int Rev Neurobiol. 2002;50:293-321 - PubMed
  11. Vasc Med. 1998;3(2):131-7 - PubMed
  12. Neurosci Lett. 2012 Apr 25;515(1):34-8 - PubMed
  13. J Biol Chem. 1999 Nov 12;274(46):33085-91 - PubMed
  14. Neuron. 2011 Jan 13;69(1):91-105 - PubMed
  15. Diabetes Care. 1995 Aug;18(8):1160-7 - PubMed
  16. Int J Mol Sci. 2012;13(7):8379-87 - PubMed
  17. Semin Cell Dev Biol. 2010 Dec;21(9):922-8 - PubMed
  18. Diabetes. 2000 Jun;49(6):1006-15 - PubMed
  19. Sci Signal. 2013 Apr 09;6(270):jc1 - PubMed
  20. Life Sci. 2012 Jan 16;90(3-4):99-108 - PubMed
  21. Mol Cancer Ther. 2006 Aug;5(8):2051-9 - PubMed
  22. J Neurosci. 2011 Jun 29;31(26):9630-40 - PubMed
  23. J Ethnopharmacol. 2004 May;92(1):1-21 - PubMed
  24. Mol Cell Neurosci. 2001 Apr;17(4):761-7 - PubMed
  25. Nucleic Acids Res. 2001 May 1;29(9):e45 - PubMed
  26. Diabetologia. 1998 Apr;41(4):390-9 - PubMed
  27. Diabetes. 2009 Nov;58(11):2677-86 - PubMed
  28. Science. 2004 Apr 30;304(5671):700-3 - PubMed
  29. Int Rev Neurobiol. 2002;50:325-92 - PubMed
  30. J Neurochem. 2010 Jan;112(1):77-91 - PubMed
  31. Diabet Med. 2001 Dec;18(12):945-59 - PubMed
  32. Mol Cell Biol. 2004 Feb;24(4):1531-9 - PubMed
  33. Diabetes Care. 2005 Apr;28(4):956-62 - PubMed
  34. Am J Pathol. 1990 Jun;136(6):1365-73 - PubMed
  35. Zhongguo Zhong Yao Za Zhi. 2007 May;32(9):775-8 - PubMed
  36. PLoS One. 2011;6(12):e28692 - PubMed
  37. Diabetes. 2005 Jun;54(6):1615-25 - PubMed
  38. Diabetes Metab Res Rev. 2012 Feb;28 Suppl 1:8-14 - PubMed

Publication Types